Bryce Point Capital LLC Makes New $1.14 Million Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

Bryce Point Capital LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, HoldingsChannel reports. The fund bought 96,550 shares of the company’s stock, valued at approximately $1,142,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Quarry LP raised its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Roivant Sciences during the fourth quarter valued at $121,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 2.3 %

ROIV opened at $10.08 on Thursday. The company’s 50 day moving average is $10.67 and its 200 day moving average is $11.36. The company has a market cap of $7.19 billion, a price-to-earnings ratio of -67.20 and a beta of 1.26. Roivant Sciences Ltd. has a 12-month low of $9.76 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ROIV shares. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $17.10.

Insider Activity at Roivant Sciences

In other news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 1,395,541 shares of company stock worth $15,028,538. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.